Highlights

• Hepatoblastomas display marked changes in the expression of epigenetic genes.

• Epigenetic transcriptome dysregulation correlates with poor clinical outcomes.

• The histone-methyltransferase G9a is a key gene in hepatoblastoma development.

• Targeting G9a activity abrogates metabolic reprogramming in hepatoblastoma cells.

• Epigenetic drugs may hold promise for the treatment of patients with hepatoblastoma.

(A. Clavería-Cabello et. Al. – Journal of Hepatology – October 2023)

Read more